Torsten W Remmerbach1,2,3,4, Jan Liese5, Sarah Krause6, Ingolf Schiefke7, Franziska Schiefke8, Melanie Maier9, Uwe G Liebert9. 1. Section of Clinical and Experimental Oral Medicine, University of Leipzig, Liebigstraße 10-14, 04103, Leipzig, Germany. torsten.remmerbach@uniklinik-leipzig.de. 2. Dental Clinic, Department of Head Medicine and Oral Health, University of Leipzig, Liebigstraße 10-14, 04103, Leipzig, Germany. torsten.remmerbach@uniklinik-leipzig.de. 3. Department of Oral & Maxillofacial and Facial Plastic Surgery, University of Leipzig, Liebigstraße 10-14, 04103, Leipzig, Germany. torsten.remmerbach@uniklinik-leipzig.de. 4. Griffith Institute of Health, Griffith University, Gold Coast Campus, Gold Coast, QLD, 4222, Australia. torsten.remmerbach@uniklinik-leipzig.de. 5. Department of Oral & Maxillofacial and Facial Plastic Surgery, University of Rostock, Rostock, Germany. 6. Section of Clinical and Experimental Oral Medicine, University of Leipzig, Liebigstraße 10-14, 04103, Leipzig, Germany. 7. Clinic of Gastroenterology and Hepatology, St. George Hospital, Leipzig, Germany. 8. Department of Oral & Maxillofacial and Facial Plastic Surgery, University of Leipzig, Liebigstraße 10-14, 04103, Leipzig, Germany. 9. Institute of Virology, University of Leipzig, Liebigstraße 10-14, 04103, Leipzig, Germany.
Abstract
OBJECTIVES: Co-occurrence of oral lichen planus (OLP) and chronic hepatitis C virus (HCV) infection suggests a strong association, but the relation between mucocutaneus, autoimmune lichen planus and HCV infection remains unclear. In areas with higher prevalence of HCV infection in general population, like Japan and southern Europe, 20 to 40 % of patients with OLP test positive for anti-HCV antibodies, whereas in German populations, a co-occurrence of 4.2 to 16 % was reported. MATERIAL AND METHODS: We screened 143 patients with histopathologically proven OLP for prevalence of anti-HCV antibodies. Additionally, we examined 51 anti-HCV-positive subjects with current or past HCV infection for clinical symptoms of OLP. In all patients, confirmatory diagnosis was made by the detection of HCV RNA via reverse transcription-polymerase chain reaction (RT-PCR). A randomized control group comprised 109 blood sera samples of patients without any characteristics of OLP. RESULTS: The results of all patients showed no co-occurrence in either cohort. CONCLUSION: In conclusion, no association between oral lichen planus and chronic HCV infection in our study population was found. CLINICAL RELEVANCE: Anti-HCV antibody screening in patients with confirmed oral lichen planus is not indicated routinely in central Germany.
OBJECTIVES: Co-occurrence of oral lichen planus (OLP) and chronic hepatitis C virus (HCV) infection suggests a strong association, but the relation between mucocutaneus, autoimmune lichen planus and HCV infection remains unclear. In areas with higher prevalence of HCV infection in general population, like Japan and southern Europe, 20 to 40 % of patients with OLP test positive for anti-HCV antibodies, whereas in German populations, a co-occurrence of 4.2 to 16 % was reported. MATERIAL AND METHODS: We screened 143 patients with histopathologically proven OLP for prevalence of anti-HCV antibodies. Additionally, we examined 51 anti-HCV-positive subjects with current or past HCV infection for clinical symptoms of OLP. In all patients, confirmatory diagnosis was made by the detection of HCV RNA via reverse transcription-polymerase chain reaction (RT-PCR). A randomized control group comprised 109 blood sera samples of patients without any characteristics of OLP. RESULTS: The results of all patients showed no co-occurrence in either cohort. CONCLUSION: In conclusion, no association between oral lichen planus and chronic HCV infection in our study population was found. CLINICAL RELEVANCE: Anti-HCV antibody screening in patients with confirmed oral lichen planus is not indicated routinely in central Germany.
Authors: William Alazawi; Mark Pett; Barbara Arch; Laurie Scott; Tom Freeman; Margaret A Stanley; Nicholas Coleman Journal: Cancer Res Date: 2002-12-01 Impact factor: 12.701
Authors: C Scully; M Beyli; M C Ferreiro; G Ficarra; Y Gill; M Griffiths; P Holmstrup; S Mutlu; S Porter; D Wray Journal: Crit Rev Oral Biol Med Date: 1998
Authors: Giovanni Lodi; Crispian Scully; Marco Carrozzo; Mark Griffiths; Philip B Sugerman; Kobkan Thongprasom Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2005-07
Authors: M Lenzi; P J Johnson; I G McFarlane; G Ballardini; H M Smith; B M McFarlane; C Bridger; D Vergani; F B Bianchi; R Williams Journal: Lancet Date: 1991-08-03 Impact factor: 79.321